Newsfeeds - Spark Newswire

4 minute read

Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

March 22, 1:56 PM

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

AEY

1 minute read

Cantor Fitzgerald Initiates Coverage On Karuna Therapeutics with Neutral Rating, Announces Price Target of $214

By Benzinga Newsdesk

March 8, 5:52 AM

Cantor Fitzgerald analyst Charles Duncan initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Neutral rating and announces Price Target of $214.

KRTX

1 minute read

Ciena, Apple And 3 Stocks To Watch Heading Into Monday

By Lisa Levin

March 6, 5:01 AM

With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

AAPL

1 minute read

HC Wainwright & Co. Reiterates Buy on Karuna Therapeutics, Maintains $320 Price Target

By Benzinga Newsdesk

February 27, 7:12 AM

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Karuna Therapeutics (NASDAQ:KRTX) with a Buy and maintains $320 price target.

KRTX

1 minute read

Analyst Ratings

Analyst Expectations for Karuna Therapeutics’s Future

By Benzinga Insights

January 27, 4:00 PM

Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

KRTX

1 minute read

UBS Initiates Coverage On Karuna Therapeutics with Neutral Rating, Announces Price Target of $209

By Benzinga Newsdesk

January 27, 9:14 AM

UBS analyst Ashwani Verma initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Neutral rating and announces Price Target of $209.

KRTX

9 minute read

FDA
News

PureTech Health Plc Provides Update On Progress Made Across Its Wholly Owned Programs And Founded Entities In 2022

By Benzinga Newsdesk

December 22, 5:42 AM

Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone).

AKLI